Fibrolamellar Hepatocellular Carcinoma Insights

Fibrolamellar hepatocellular carcinoma (FLC) is a distinctive liver cancer that predominantly affects adolescents and young adults without underlying chronic liver disease. Characterised by a pathognomonic fusion between DNAJB1 and PRKACA genes, FLC displays unique histological features including lamellar fibrosis and large polygonal tumour cells with abundant mitochondria. Despite its rarity, recent advances have illuminated the molecular drivers of FLC, revealing altered protein kinase A signalling, non-coding RNA signatures and metabolic dysregulation. Experimental models—from engineered organoids to patient-derived xenografts—have begun to unravel mechanisms of tumour initiation, cellular plasticity and stem-cell-like traits, paving the way for targeted interventions. Clinically, accurate diagnosis remains challenging but has been enhanced by molecular assays, while novel therapeutic vulnerabilities have emerged through high-throughput drug screening. Ongoing research addresses early detection, prognostic factors and precision-medicine approaches to improve outcomes for this aggressive yet molecularly tractable malignancy.

Research from Nature Portfolio

Recent studies have engineered human hepatocyte organoids harbouring FLC-associated mutations to recreate the DNAJB1-PRKACA fusion and concurrent BAP1/PRKAR2A inactivation. These models demonstrated hepatocyte dedifferentiation and, uniquely with combined BAP1 and PRKAR2A loss, transdifferentiation into ductal-like progenitors. Complementing this, comprehensive analysis of large-scale tumour sequencing identified a distinct mRNA and long intergenic non-coding RNA signature specific to FLC, implicating aberrant protein kinase A activity and novel candidate oncogenes such as carbonic anhydrase XII. Foundational work with a transplantable tumour line in immunodeficient mice further validated the DNAJB1-PRKACA fusion and revealed enrichment of cancer stem cells with a gene expression profile resembling biliary tree stem cells. Together, these insights establish robust preclinical platforms and molecular frameworks for dissecting FLC pathogenesis and evaluating targeted strategies.

Fibrolamellar Hepatocellular Carcinoma Insights publication trend

The graph below shows the total number of articles in fibrolamellar hepatocellular carcinoma insights across all publications each year (not limited to Nature Index journals).

Technical terms

DNAJB1-PRKACA fusion: A somatic gene fusion that constitutively activates protein kinase A, defining FLC at the molecular level.

Organoid: A three-dimensional cell culture system derived from primary cells that recapitulates key features of the original tissue or tumour.

Long intergenic non-coding RNA (lincRNA): A class of non-coding RNA molecules located between genes, implicated in regulation of gene expression.

Patient-derived xenograft: A model in which human tumour tissue is implanted into immunodeficient mice to study cancer biology and drug response.

Fluorescence in situ hybridisation (FISH): A molecular technique for detecting specific DNA sequences, used to confirm gene rearrangements in clinical samples.

References

1. Organoid models of fibrolamellar carcinoma mutations reveal hepatocyte transdifferentiation through cooperative BAP1 and PRKAR2A loss. Nature Communications (2023).
2. Comprehensive analysis of The Cancer Genome Atlas reveals a unique gene and non-coding RNA signature of fibrolamellar carcinoma. Scientific Reports (2017).
3. Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cells. Nature Communications (2015).
4. Defining incidence and complications of fibrolamellar liver cancer through tiered computational analysis of clinical data. npj Precision Oncology (2023).
5. Molecular testing for the clinical diagnosis of fibrolamellar carcinoma. Modern Pathology (2017).
6. Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient Derived Xenografts and Direct from Patient Screening. Cancer Discovery (2021).